Quantcast
Last updated on April 18, 2014 at 1:21 EDT

Latest Molecular biologists Stories

2014-03-10 08:29:58

SAN FRANCISCO, March 10, 2014 /PRNewswire/ -- Alector, LLC announced today a collaborative research agreement facilitated by the Johnson & Johnson Innovation Center in California. Under the agreement, Janssen Pharmaceuticals, Inc. will fund research in one of Alector's targets through proof-of-concept disease models and will retain a time-limited option to negotiate a commercial agreement. Arnon Rosenthal, Ph.D., President and Chief Executive Officer of Alector, said, "As part...

2013-09-10 23:19:50

As VP of Business Development & Technology Transfer, Willey will build on strong record of success in venture capital and research commercialization Cold Spring Harbor, NY (PRWEB) September 10, 2013 Cold Spring Harbor Laboratory (CSHL) today announced that Teri F. Willey has been appointed Vice President of Business Development and Technology Transfer. In this newly created position, Ms. Willey will direct the Laboratory’s commercialization and technology transfer activities,...

2013-09-02 00:20:34

SAN DIEGO, Sept. 2, 2013 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) announced today that the European Commission has granted Roche European Union (EU) marketing authorization for the use of a time-saving subcutaneous (SC) formulation of Herceptin(®) (trastuzumab) for the treatment of HER2-positive breast cancer. This formulation utilizes Halozyme's recombinant human hyaluronidase (rHuPH20) and is administered in two to five minutes, rather than 30 to 90 minutes with...

2013-06-03 23:14:07

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes ℠s expression – among them mutations, amplifications, substitutions, and translocations – have been found in 14 different advanced solid tumors. Chicago, Illinois (PRWEB) June 03, 2013 The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes ℠s expression...

2013-06-03 20:21:14

Phase 2 Clinical Trial Underway to Evaluate Activity in Patients with Advanced Breast Cancer ROCKVILLE, Md., June 3, 2013 /PRNewswire/ -- MacroGenics, Inc. announced that results of the first-in-human study of margetuximab were reported during an oral abstract session today at the 2013 Annual Meeting of the American Society of Clinical Oncology (ASCO). Howard A. Burris, M.D., FACP, first author and Chief Medical Officer of Sarah Cannon Research Institute, presented "Phase 1 study of...

2013-06-03 12:32:40

The HER2 growth-factor gene is known to be over-active in breast and gastro-esophageal cancers. But now, irregularities in the genes 's expression – among them mutations, amplifications, substitutions, and translocations – have been found in 14 different advanced solid tumors. The results of the study of more than 2,000 tumors, being presented at the annual meeting of the American Society of Clinical Oncology (ASCO), both surprised researchers and provided hope that some of...

2013-05-21 08:28:18

ROCKVILLE, Md., May 21, 2013 /PRNewswire/ -- MacroGenics, Inc. today announced that an abstract titled, "Phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody (MAb), in patients with advanced solid tumors expressing the HER2 oncoprotein," will be presented at the 2013 Annual Meeting of the American Society of Clinical Oncology during the Developmental Therapeutics - Immunotherapy Oral Abstract Session on Monday, June 3 at 4:15 - 4:30 PM. The presentation will...

2013-04-18 21:36:57

It is rare that an unpublished piece of research or theory remains significant after half a century. It is also a wonderful example of the boundless curiosity of the late Francis Crick. A previously unpublished work by Francis Crick and Jeffries Wyman from 1965 is now available, together with Jean-Pierre Changeux's recollections on the origins of the theory of Allostery and several important texts by various authors on the subject. These are part of a special issue of the Journal of Molecular...

2013-04-09 12:29:00

BURLINGAME, Calif., April 9, 2013 /PRNewswire/ -- Igenica, Inc., an innovative biopharmaceutical company focused on the discovery and development of first-in-class antibody-based therapeutics for the treatment of cancer, today announced the appointment of Thi-Sau Migone, Ph.D., to the role of Chief Scientific Officer. Dr. Migone brings wide-ranging experience in the discovery and development of novel therapeutic antibodies. Dr. Migone joins Igenica from Human Genome Sciences,...

DNA Discoverer's Letter To Be Auctioned Off
2013-03-25 05:26:50

redOrbit Staff & Wire Reports - Your Universe Online A handwritten letter sent from one of the scientists responsible for discovering the structure of DNA will be auctioned off next month in New York City, according to various media reports. In the letter, which was written on March 19, 1953, British molecular biologist and biophysicist Francis Crick explains to his then-12-year-old son Michael how he and colleague James Watson were able to create a model for the genetic...